Ensifentrine (pMDI)
Maintenance Treatment of COPD
Key Facts
About Verona Pharma
Verona Pharma was an independent, London-based biopharmaceutical company dedicated to advancing novel treatments for chronic respiratory diseases, with its entire strategy centered on the development of ensifentrine. The company's key achievement was the successful clinical development of this first-in-class, dual PDE3/PDE4 inhibitor, leading to its acquisition by Merck & Co., Inc. (MSD) in October 2025. This strategic acquisition transitioned Verona into a well-resourced subsidiary, leveraging MSD's global commercial and development capabilities to maximize the potential of ensifentrine in major markets like COPD and beyond. The deal represents a successful exit for shareholders and a validation of the company's innovative scientific platform.
View full company profileTherapeutic Areas
Other Maintenance Treatment of COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Ensifentrine (Nebulized) | Verona Pharma | Approved |